Log in

NASDAQ:RDHL - REDHILL BIOPHAR/S Stock Price, Forecast & News

$4.21
-0.22 (-4.97 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$4.20
Now: $4.21
$4.60
50-Day Range
$3.51
MA: $4.51
$5.06
52-Week Range
$3.26
Now: $4.21
$8.94
Volume95,869 shs
Average Volume276,707 shs
Market Capitalization$92.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors. It is also developing YELIVA that is in Phase IIa clinical trial for the treatment of advanced unresectable cholangiocarcinoma; is in Phase Ib/II clinical trial for refractory or relapsed multiple myeloma; and is in Phase II clinical trial for the treatment of advanced hepatocellular carcinoma. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
Read More
REDHILL BIOPHAR/S logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDHL
CUSIPN/A
Phone972-3541-3131

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.29 million
Book Value$2.74 per share

Profitability

Net Income$-42,300,000.00
Net Margins-672.45%

Miscellaneous

Employees75
Market Cap$92.37 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive RDHL News and Ratings via Email

Sign-up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.


REDHILL BIOPHAR/S (NASDAQ:RDHL) Frequently Asked Questions

How has REDHILL BIOPHAR/S's stock been impacted by COVID-19 (Coronavirus)?

REDHILL BIOPHAR/S's stock was trading at $3.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RDHL stock has increased by 5.5% and is now trading at $4.21. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of REDHILL BIOPHAR/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REDHILL BIOPHAR/S in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for REDHILL BIOPHAR/S.

When is REDHILL BIOPHAR/S's next earnings date?

REDHILL BIOPHAR/S is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for REDHILL BIOPHAR/S.

How were REDHILL BIOPHAR/S's earnings last quarter?

REDHILL BIOPHAR/S (NASDAQ:RDHL) announced its earnings results on Wednesday, March, 4th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.02. The biotechnology company earned $1.59 million during the quarter, compared to the consensus estimate of $1.34 million. REDHILL BIOPHAR/S had a negative return on equity of 108.03% and a negative net margin of 672.45%. View REDHILL BIOPHAR/S's earnings history.

What price target have analysts set for RDHL?

3 equities research analysts have issued 12-month price objectives for REDHILL BIOPHAR/S's shares. Their forecasts range from $14.00 to $23.00. On average, they expect REDHILL BIOPHAR/S's stock price to reach $17.25 in the next year. This suggests a possible upside of 309.7% from the stock's current price. View analysts' price targets for REDHILL BIOPHAR/S.

Has REDHILL BIOPHAR/S been receiving favorable news coverage?

Media stories about RDHL stock have been trending extremely negative on Sunday, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. REDHILL BIOPHAR/S earned a news impact score of -4.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutREDHILL BIOPHAR/S.

Who are some of REDHILL BIOPHAR/S's key competitors?

What other stocks do shareholders of REDHILL BIOPHAR/S own?

Who are REDHILL BIOPHAR/S's key executives?

REDHILL BIOPHAR/S's management team includes the following people:
  • Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 53)
  • Mr. Micha Ben-Chorin, Chief Financial Officer (Age 50)
  • Mr. Gilead Raday, Chief Operating Officer (Age 44)
  • Mr. Adi Frish, Sr. VP of Bus. Devel. & Licensing (Age 49)
  • Mr. Guy Goldberg, Chief Bus. Officer (Age 43)

What is REDHILL BIOPHAR/S's stock symbol?

REDHILL BIOPHAR/S trades on the NASDAQ under the ticker symbol "RDHL."

Who are REDHILL BIOPHAR/S's major shareholders?

REDHILL BIOPHAR/S's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ibex Investors LLC (7.99%), Creative Planning (1.76%), Gagnon Securities LLC (0.51%), State Street Corp (0.36%), ARK Investment Management LLC (0.27%) and Sanders Morris Harris LLC (0.22%).

Which major investors are selling REDHILL BIOPHAR/S stock?

RDHL stock was sold by a variety of institutional investors in the last quarter, including Ibex Investors LLC, Boston Partners, and Sanders Morris Harris LLC.

Which major investors are buying REDHILL BIOPHAR/S stock?

RDHL stock was purchased by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, Creative Planning, State Street Corp, Ingalls & Snyder LLC, Schonfeld Strategic Advisors LLC, Bank of New York Mellon Corp, Virtu Financial LLC, and Sowell Financial Services LLC.

How do I buy shares of REDHILL BIOPHAR/S?

Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is REDHILL BIOPHAR/S's stock price today?

One share of RDHL stock can currently be purchased for approximately $4.21.

How big of a company is REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S has a market capitalization of $92.37 million and generates $6.29 million in revenue each year. The biotechnology company earns $-42,300,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. REDHILL BIOPHAR/S employs 75 workers across the globe. View additional information about REDHILL BIOPHAR/S.

What is REDHILL BIOPHAR/S's official website?

The official website for REDHILL BIOPHAR/S is http://www.redhillbio.com/.

How can I contact REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The biotechnology company can be reached via phone at 972-3541-3131 or via email at [email protected]


MarketBeat Community Rating for REDHILL BIOPHAR/S (NASDAQ RDHL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  393 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  666
MarketBeat's community ratings are surveys of what our community members think about REDHILL BIOPHAR/S and other stocks. Vote "Outperform" if you believe RDHL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDHL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel